| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*See page 910 for Committee members.
From the Department of Neurology (Dr. Lublin), Jefferson Medical College, Philadelphia, PA; and the Research and Medical Programs Department (Dr. Reingold), National Multiple Sclerosis Society (USA), New York, NY.
Received August 9, 1995. Accepted in final form August 18, 1995.
Address correspondence and reprint requests to Dr Lublin, Department of Neurology, Jefferson Medical College, Philadelphia, PA.
Standardization of terminology used to describe the pattern and course of MS is essential for mutual understanding between clinicians and investigators.It is particularly important in design of, and recruitment for, clinical trials statistically powered for expected outcomes for given patient populations with narrowly defined entry criteria. For agents that prove safe and effective for MS, knowledge of the patient populations in definitive clinical trials assists clinicians in determining who may ultimately benefit from use of the medication. An international survey of clinicians involved with MS revealed areas of consensus about some terms classically used to describe types of the disease and other areas for which there was lack of consensus. In this report, we provide a summary of the survey results and propose standardized definitions for the most common clinical courses of patients with MS.
NEUROLOGY 1996;46: 907-911
This article has been cited by other articles:
|
|
 |
|
  A. Awad and O. Stuve Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms Therapeutic Advances in Neurological Disorders, November 1, 2009; 2(6): 357 - 368. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Smestad, L. Sandvik, and E. Celius Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients Multiple Sclerosis, November 1, 2009; 15(11): 1263 - 1270. [Abstract] [PDF]
|
|
|
|
|
|
P. Veugelers, J. Fisk, M. Brown, K. Stadnyk, I. Sketris, T. Murray, and V. Bhan Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation Multiple Sclerosis, November 1, 2009; 15(11): 1286 - 1294. [Abstract] [PDF]
|
|
|
|
 |
|
 M.P. Sampat, A.M. Berger, B.C. Healy, P. Hildenbrand, J. Vass, D.S. Meier, T. Chitnis, H.L. Weiner, R. Bakshi, and C.R.G. Guttmann Regional White Matter Atrophy-Based Classification of Multiple Sclerosis in Cross-Sectional and Longitudinal Data AJNR Am. J. Neuroradiol., October 1, 2009; 30(9): 1731 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M H J Vogt, C E Teunissen, E Iacobaeus, D A M Heijnen, E C W Breij, T Olsson, L Brundin, J Killestein, and C. D Dijkstra Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1110 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Montalban, J. Sastre-Garriga, M. Tintore, L. Brieva, F. Aymerich, J. Rio, J. Porcel, C. Borras, C. Nos, and A. Rovira A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis Multiple Sclerosis, October 1, 2009; 15(10): 1195 - 1205. [Abstract] [PDF]
|
|
|
|
 |
|
 U. Walter, S. Wagner, S. Horowski, R. Benecke, and U. K. Zettl Transcranial brain sonography findings predict disease progression in multiple sclerosis Neurology, September 29, 2009; 73(13): 1010 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Staff, C. F. Lucchinetti, and B. M. Keegan Multiple Sclerosis With Predominant, Severe Cognitive Impairment Arch Neurol, September 1, 2009; 66(9): 1139 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Calabrese, F. Agosta, F. Rinaldi, I. Mattisi, P. Grossi, A. Favaretto, M. Atzori, V. Bernardi, L. Barachino, L. Rinaldi, et al. Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Arch Neurol, September 1, 2009; 66(9): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Ukkonen, T Vahvelainen, P Hamalainen, P Dastidar, and I Elovaara Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study Multiple Sclerosis, September 1, 2009; 15(9): 1055 - 1061. [Abstract] [PDF]
|
|
|
|
|
|
L Strober, J Englert, F Munschauer, B Weinstock-Guttman, S Rao, and R. Benedict Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS Multiple Sclerosis, September 1, 2009; 15(9): 1077 - 1084. [Abstract] [PDF]
|
|
|
|
|
|
R. Zivadinov, B. Weinstock-Guttman, K. Hashmi, N. Abdelrahman, M. Stosic, M. Dwyer, S. Hussein, J. Durfee, and M. Ramanathan Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis Neurology, August 18, 2009; 73(7): 504 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Portaccio, M. L. Stromillo, B. Goretti, V. Zipoli, G. Siracusa, M. Battaglini, A. Giorgio, M. L. Bartolozzi, L. Guidi, S. Sorbi, et al. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis Neurology, August 18, 2009; 73(7): 498 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H.B. Benedict and F. Fazekas Benign or not benign MS: A role for routine neuropsychological assessment? Neurology, August 18, 2009; 73(7): 494 - 495. [Full Text] [PDF]
|
|
|
|
|
|
F. Tovar-Moll, I.E. Evangelou, A.W. Chiu, N.D. Richert, J.L. Ostuni, J.M. Ohayon, S. Auh, M. Ehrmantraut, S.L. Talagala, H.F. McFarland, et al. Thalamic Involvement and Its Impact on Clinical Disability in Patients with Multiple Sclerosis: A Diffusion Tensor Imaging Study at 3T AJNR Am. J. Neuroradiol., August 1, 2009; 30(7): 1380 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Glad, H. Nyland, J. Aarseth, T Riise, and K. Myhr Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway Multiple Sclerosis, August 1, 2009; 15(8): 942 - 950. [Abstract] [PDF]
|
|
|
|
|
|
R. A. Farrell, D. Antony, G. R. Wall, D. A. Clark, L. Fisniku, J. Swanton, Z. Khaleeli, K. Schmierer, D. H. Miller, and G. Giovannoni Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI Neurology, July 7, 2009; 73(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Radziszewski, R Crayton, J Zaborski, A Czlonkowska, A Borkowski, A Bossowska, and M Majewski Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity Multiple Sclerosis, July 1, 2009; 15(7): 860 - 868. [Abstract] [PDF]
|
|
|
|
|
|
B Benedetti, M Rovaris, M. Rocca, D Caputo, M Zaffaroni, R Capra, A Bertolotto, V Martinelli, G Comi, and M Filippi In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis Multiple Sclerosis, July 1, 2009; 15(7): 789 - 794. [Abstract] [PDF]
|
|
|
|
|
|
V. Anderson, L. Fisniku, D. Altmann, A. Thompson, and D. Miller MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction Multiple Sclerosis, July 1, 2009; 15(7): 811 - 817. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Kremer, A. Heinen, J. Jadasz, P. Gottle, K. Zimmermann, P. Zickler, S. Jander, H.-P. Hartung, and P. Kury p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation PNAS, June 2, 2009; 106(22): 9087 - 9092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Ceccarelli, M Filippi, M Neema, A Arora, P Valsasina, M. Rocca, B. Healy, and R Bakshi T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis Multiple Sclerosis, June 1, 2009; 15(6): 678 - 686. [Abstract] [PDF]
|
|
|
|
|
|
R Zivadinov, M Zorzon, B Weinstock-Guttman, M Serafin, A Bosco, A Bratina, C Maggiore, A Grop, M A Tommasi, B Srinivasaraghavan, et al. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bosma, J. Kragt, L Brieva, Z Khaleeli, X Montalban, C. Polman, A. Thompson, M Tintore, and B. Uitdehaag The search for responsive clinical endpoints in primary progressive multiple sclerosis Multiple Sclerosis, June 1, 2009; 15(6): 715 - 720. [Abstract] [PDF]
|
|
|
|
|
|
L. Fisniku, D. Altmann, M Cercignani, D. Tozer, D. Chard, J. Jackson, K. Miszkiel, K Schmierer, A. Thompson, and D. Miller Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis Multiple Sclerosis, June 1, 2009; 15(6): 668 - 677. [Abstract] [PDF]
|
|
|
|
|
|
S. Roosendaal, B Moraal, P. Pouwels, H Vrenken, J. Castelijns, F Barkhof, and J. Geurts Accumulation of cortical lesions in MS: relation with cognitive impairment Multiple Sclerosis, June 1, 2009; 15(6): 708 - 714. [Abstract] [PDF]
|
|
|
|
|
|
M. Rovaris, F. Barkhof, M. Calabrese, N. De Stefano, F. Fazekas, D. H. Miller, X. Montalban, C. Polman, M. A. Rocca, A. J. Thompson, et al. MRI features of benign multiple sclerosis: Toward a new definition of this disease phenotype Neurology, May 12, 2009; 72(19): 1693 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Minneboo, B. Uitdehaag, P Jongen, H Vrenken, D. Knol, M. van Walderveen, C. Polman, J. Castelijns, and F Barkhof Association between MRI parameters and the MS severity scale: a 12 year follow-up study Multiple Sclerosis, May 1, 2009; 15(5): 632 - 637. [Abstract] [PDF]
|
|
|
|
|
|
A. Seewann, H. Vrenken, P. van der Valk, E. L. A. Blezer, D. L. Knol, J. A. Castelijns, C. H. Polman, P. J. W. Pouwels, F. Barkhof, and J. J. G. Geurts Diffusely Abnormal White Matter in Chronic Multiple Sclerosis: Imaging and Histopathologic Analysis Arch Neurol, May 1, 2009; 66(5): 601 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Fainardi, M Castellazzi, C Tamborino, A Trentini, M. Manfrinato, E Baldi, M. Tola, F Dallocchio, E Granieri, and T Bellini Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 547 - 554. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Roccatagliata, L. Vuolo, L. Bonzano, A. Pichiecchio, and G. L. Mancardi Multiple Sclerosis: Hyperintense Dentate Nucleus on Unenhanced T1-weighted MR Images Is Associated with the Secondary Progressive Subtype Radiology, May 1, 2009; 251(2): 503 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Correale, M. C. Ysrraelit, and M. I. Gaitan Immunomodulatory effects of Vitamin D in multiple sclerosis Brain, May 1, 2009; 132(5): 1146 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Frischer, S. Bramow, A. Dal-Bianco, C. F. Lucchinetti, H. Rauschka, M. Schmidbauer, H. Laursen, P. S. Sorensen, and H. Lassmann The relation between inflammation and neurodegeneration in multiple sclerosis brains Brain, May 1, 2009; 132(5): 1175 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Teunissen, E. Iacobaeus, M. Khademi, L. Brundin, N. Norgren, M.J.A. Koel-Simmelink, M. Schepens, F. Bouwman, H. A.M. Twaalfhoven, H. J. Blom, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis Neurology, April 14, 2009; 72(15): 1322 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Zamboni, R Galeotti, E Menegatti, A M Malagoni, G Tacconi, S Dall'Ara, I Bartolomei, and F Salvi Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 392 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Korteweg, M Rovaris, V Neacsu, M Filippi, G Comi, B. Uitdehaag, D. Knol, C. Polman, F Barkhof, H Vrenken, et al. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Multiple Sclerosis, April 1, 2009; 15(4): 465 - 471. [Abstract] [PDF]
|
|
|
|
|
|
A. D. Goodman, H. Rossman, A. Bar-Or, A. Miller, D. H. Miller, K. Schmierer, F. Lublin, O. Khan, N. M. Bormann, M. Yang, et al. GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study Neurology, March 3, 2009; 72(9): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Lincoln, D. Cadavid, J. Pollard, J. McLeod, J. Prineas, P. Dowling, and S. D. Cook We Should Use Magnetic Resonance Imaging to Classify and Monitor the Course of Multiple Sclerosis Arch Neurol, March 1, 2009; 66(3): 412 - 414. [Full Text] [PDF]
|
|
|
|
|
|
R Antulov, B Weinstock-Guttman, J. Cox, S Hussein, J Durfee, C Caiola, M. Dwyer, N Bergsland, N Abdelrahman, M Stosic, et al. Gender-related differences in MS: a study of conventional and nonconventional MRI measures Multiple Sclerosis, March 1, 2009; 15(3): 345 - 354. [Abstract] [PDF]
|
|
|
|
|
|
M Filippi, M Calabrese, and P Gallo Response letter regarding the article "Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study," by Calabrese, et al. Multiple Sclerosis, March 1, 2009; 15(3): 404 - 404. [PDF]
|
|
|
|
|
|
J. A. Cohen, P. B. Imrey, P. A. Calabresi, K. R. Edwards, T. Eickenhorst, W. L. Felton III, E. Fisher, R. J. Fox, A. D. Goodman, C. Hara-Cleaver, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS Neurology, February 10, 2009; 72(6): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Debouverie, L Laforest, E Van Ganse, F Guillemin, and for the LORSEP Group Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients Multiple Sclerosis, February 1, 2009; 15(2): 251 - 257. [Abstract] [PDF]
|
|
|
|
|
|
R H B Benedict, D Ramasamy, F Munschauer, B Weinstock-Guttman, and R Zivadinov Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy J. Neurol. Neurosurg. Psychiatry, February 1, 2009; 80(2): 201 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Vanotti, R. Benedict, L Acion, F Caceres, and and VANEM Workgroup Validation of the Multiple Sclerosis Neuropsychological Screening Questionnaire in Argentina Multiple Sclerosis, February 1, 2009; 15(2): 244 - 250. [Abstract] [PDF]
|
|
|
|
|
|
I. S. Haussleiter, M. Brune, and G. Juckel Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 13 - 29. [Abstract] [PDF]
|
|
|
|
|
|
J. Kragt, B. van Amerongen, J Killestein, C. Dijkstra, B. Uitdehaag, C. Polman, and P Lips Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women Multiple Sclerosis, January 1, 2009; 15(1): 9 - 15. [Abstract] [PDF]
|
|
|
|
|
|
M Calabrese, M Filippi, M Rovaris, V Bernardi, M Atzori, I Mattisi, A Favaretto, P Grossi, L Barachino, L Rinaldi, et al. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study Multiple Sclerosis, January 1, 2009; 15(1): 36 - 41. [Abstract] [PDF]
|
|
|
|
 |
|
 M. B. Forrester, L. Coleman, and A. J. Kornberg Multiple Sclerosis in Childhood: Clinical and Radiological Features J Child Neurol, January 1, 2009; 24(1): 56 - 62. [Abstract] [PDF]
|
|
|
|
|
|
M. C. Ysrraelit, M. I. Gaitan, A. S. Lopez, and J. Correale Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis Neurology, December 9, 2008; 71(24): 1948 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C E Teunissen, J Killestein, J J Kragt, C H Polman, C D Dijkstra, and H J Blom Serum homocysteine levels in relation to clinical progression in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, December 1, 2008; 79(12): 1349 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rovaris, G. Riccitelli, E. Judica, F. Possa, D. Caputo, A. Ghezzi, A. Bertolotto, R. Capra, M. Falautano, F. Mattioli, et al. Cognitive impairment and structural brain damage in benign multiple sclerosis Neurology, November 4, 2008; 71(19): 1521 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Costelloe, A Thompson, C Walsh, N Tubridy, and M Hutchinson Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease J. Neurol. Neurosurg. Psychiatry, November 1, 2008; 79(11): 1245 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Di Filippo, L A Pini, G P Pelliccioli, P Calabresi, and P Sarchielli Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2008; 79(11): 1224 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Prakash, E. Snook, J. Lewis, R. Motl, and A. Kramer Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis Multiple Sclerosis, November 1, 2008; 14(9): 1250 - 1261. [Abstract] [PDF]
|
|
|
|
|
|
M Thangarajh, J Gomez-Rial, A. Hedstrom, J Hillert, J. Alvarez-Cermeno, T Masterman, and L. Villar Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis Multiple Sclerosis, November 1, 2008; 14(9): 1208 - 1213. [Abstract] [PDF]
|
|
|
|
|
|
R. Bakshi, M. Neema, B. C. Healy, Z. Liptak, R. A. Betensky, G. J. Buckle, S. A. Gauthier, J. Stankiewicz, D. Meier, S. Egorova, et al. Predicting Clinical Progression in Multiple Sclerosis With the Magnetic Resonance Disease Severity Scale Arch Neurol, November 1, 2008; 65(11): 1449 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saresella, I. Marventano, R. Longhi, F. Lissoni, D. Trabattoni, L. Mendozzi, D. Caputo, and M. Clerici CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy FASEB J, October 1, 2008; 22(10): 3500 - 3508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Liptak, A.M. Berger, M.P. Sampat, A. Charil, O. Felsovalyi, B.C. Healy, P. Hildenbrand, S.J. Khoury, H.L. Weiner, R. Bakshi, et al. Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis AJNR Am. J. Neuroradiol., September 1, 2008; 29(8): 1465 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mesaros, M. Rovaris, E. Pagani, A. Pulizzi, D. Caputo, A. Ghezzi, A. Bertolotto, R. Capra, M. Falautano, V. Martinelli, et al. A Magnetic Resonance Imaging Voxel-Based Morphometry Study of Regional Gray Matter Atrophy in Patients With Benign Multiple Sclerosis Arch Neurol, September 1, 2008; 65(9): 1223 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Amato, E. Portaccio, M. L. Stromillo, B. Goretti, V. Zipoli, G. Siracusa, M. Battaglini, A. Giorgio, M. L. Bartolozzi, L. Guidi, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis Neurology, August 26, 2008; 71(9): 632 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Benedict, J. Duquin, S Jurgensen, R. Rudick, J Feitcher, F. Munschauer, M. Panzara, and B Weinstock-Guttman Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire Multiple Sclerosis, August 1, 2008; 14(7): 940 - 946. [Abstract] [PDF]
|
|
|
|
|
|
K Wynia, B Middel, J. van Dijk, J. De Keyser, and S. Reijneveld The impact of disabilities on quality of life in people with multiple sclerosis Multiple Sclerosis, August 1, 2008; 14(7): 972 - 980. [Abstract] [PDF]
|
|
|
|
|
|
F. Fazekas, F. D. Lublin, D. Li, M. S. Freedman, H. P. Hartung, P. Rieckmann, P. S. Sorensen, M. Maas-Enriquez, B. Sommerauer, K. Hanna, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial Neurology, July 22, 2008; 71(4): 265 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Iarlori, D Gambi, A Lugaresi, A Patruno, M Felaco, M Salvatore, L Speranza, and M Reale Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone(R)) Multiple Sclerosis, July 1, 2008; 14(6): 739 - 748. [Abstract] [PDF]
|
|
|
|
|
|
J Kraus, K Voigt, A. Schuller, M Scholz, K. Kim, M Schilling, W. Schabitz, P Oschmann, and B Engelhardt Interferon-{beta} stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro Multiple Sclerosis, July 1, 2008; 14(6): 843 - 852. [Abstract] [PDF]
|
|
|
|
|
|
M Koch, J De Keyser, and H Tremlett Timing of birth and disease progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 793 - 798. [Abstract] [PDF]
|
|
|
|
|
|
F. Tecchio, G. Zito, F. Zappasodi, M. L. Dell' Acqua, D. Landi, D. Nardo, D. Lupoi, P. M. Rossini, and M. M. Filippi Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach Brain, July 1, 2008; 131(7): 1783 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Lucchinetti, R. H. Gavrilova, I. Metz, J. E. Parisi, B. W. Scheithauer, S. Weigand, K. Thomsen, J. Mandrekar, A. Altintas, B. J. Erickson, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis Brain, July 1, 2008; 131(7): 1759 - 1775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Williams, H. J. Skinner, and B. L. Maria Increased Intracranial Pressure in a Case of Pediatric Multiple Sclerosis J Child Neurol, June 1, 2008; 23(6): 699 - 702. [Abstract] [PDF]
|
|
|
|
|
|
A. Hebb, C. Moore, V Bhan, T Campbell, J. Fisk, H. Robertson, M Thorne, E Lacasse, M Holcik, J Gillard, et al. Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination Multiple Sclerosis, June 1, 2008; 14(5): 577 - 594. [Abstract] [PDF]
|
|
|
|
|
|
S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655. [Abstract] [PDF]
|
|
|
|
|
|
M. Melcon, L Gold, A Carra, F Caceres, J Correale, E Cristiano, N Fernandez Liguori, O Garcea, G Luetic, M Kremenchutzky, et al. Argentine Patagonia: prevalence and clinical features of multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 656 - 662. [Abstract] [PDF]
|
|
|
|
|
|
S Bramow, J. Faber-Rod, C Jacobsen, A Kutzelnigg, P Patrikios, P. Sorensen, H Lassmann, and H Laursen Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 711 - 715. [Abstract] [PDF]
|
|
|
|
|
|
F Martinelli Boneschi, B Colombo, P Annovazzi, V Martinelli, L Bernasconi, C Solaro, and G Comi Lifetime and actual prevalence of pain and headache in multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 514 - 521. [Abstract] [PDF]
|
|
|
|
|
|
D. Galimberti, C. Fenoglio, C. Comi, D. Scalabrini, M. De Riz, M. Leone, E. Venturelli, F. Cortini, M. Piola, F. Monaco, et al. MDC/CCL22 intrathecal levels in patients with multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 547 - 549. [Abstract] [PDF]
|
|
|
|
|
|
R. Marignier, J. De Seze, S. Vukusic, F. Durand-Dubief, H. Zephir, P. Vermersch, P. Cabre, G. Cavillon, J. Honnorat, and C. Confavreux NMO-IgG and Devic's neuromyelitis optica: a French experience Multiple Sclerosis, May 1, 2008; 14(4): 440 - 445. [Abstract] [PDF]
|
|
|
|
|
|
A. Miller, V. Spada, D. Beerkircher, and R. R. Kreitman Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing--remitting multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 494 - 499. [Abstract] [PDF]
|
|
|
|
|
|
E. Fainardi, R. Rizzo, L. Melchiorri, M. Stignani, M. Castellazzi, C. Tamborino, E. Paolino, M. Tola, E. Granieri, and O. Baricordi CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing--remitting multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 446 - 454. [Abstract] [PDF]
|
|
|
|
|
|
M. D Goldman, R. A. Marrie, and J. A Cohen Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls Multiple Sclerosis, April 1, 2008; 14(3): 383 - 390. [Abstract] [PDF]
|
|
|
|
|
|
H. Tremlett, Yinshan Zhao, and V. Devonshire Natural history of secondary-progressive multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 314 - 324. [Abstract] [PDF]
|
|
|
|
|
|
J. Parratt, R. Tavendale, J. O'Riordan, D. Parratt, and R. Swingler Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 292 - 299. [Abstract] [PDF]
|
|
|
|
|
|
N. L. Sicotte, K. C. Kern, B. S. Giesser, A. Arshanapalli, A. Schultz, M. Montag, H. Wang, and S. Y. Bookheimer Regional hippocampal atrophy in multiple sclerosis Brain, April 1, 2008; 131(4): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Minden, D. C. Hoaglin, L. Hadden, D. Frankel, T. Robbins, and J. Perloff Access to and utilization of neurologists by people with multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1141 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kragt, A. J. Thompson, X. Montalban, M. Tintore, J. Rio, C. H. Polman, and B.M.J. Uitdehaag Responsiveness and predictive value of EDSS and MSFC in primary progressive MS Neurology, March 25, 2008; 70(13_Part_2): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Strasser-Fuchs, C. Enzinger, S. Ropele, M. Wallner, and F. Fazekas Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox? Multiple Sclerosis, March 1, 2008; 14(2): 205 - 211. [Abstract] [PDF]
|
|
|
|
|
|
L. K. Fisniku, P. A. Brex, D. R. Altmann, K. A. Miszkiel, C. E. Benton, R. Lanyon, A. J. Thompson, and D. H. Miller Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis Brain, March 1, 2008; 131(3): 808 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zivadinov, A.C. Banas, V. Yella, N. Abdelrahman, B. Weinstock-Guttman, and M.G. Dwyer Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Di Perri, M. Battaglini, M. L. Stromillo, M. L. Bartolozzi, L. Guidi, A. Federico, and N. De Stefano Voxel-Based Assessment of Differences in Damage and Distribution of White Matter Lesions Between Patients With Primary Progressive and Relapsing-Remitting Multiple Sclerosis Arch Neurol, February 1, 2008; 65(2): 236 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. D. Henderson, S. A. Trip, P. G. Schlottmann, D. R. Altmann, D. F. Garway-Heath, G. T. Plant, and D. H. Miller An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography Brain, January 1, 2008; 131(1): 277 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.A. Marrie and M. Goldman Validity of performance scales for disability assessment in multiple sclerosis Multiple Sclerosis, November 1, 2007; 13(9): 1176 - 1182. [Abstract] [PDF]
|
|
|
|
|
|
M. G. Brown, S. Kirby, C. Skedgel, J. D. Fisk, T. J. Murray, V. Bhan, and I. S. Sketris How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, October 9, 2007; 69(15): 1498 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Calabrese, N. De Stefano, M. Atzori, V. Bernardi, I. Mattisi, L. Barachino, A. Morra, L. Rinaldi, C. Romualdi, P. Perini, et al. Detection of Cortical Inflammatory Lesions by Double Inversion Recovery Magnetic Resonance Imaging in Patients With Multiple Sclerosis Arch Neurol, October 1, 2007; 64(10): 1416 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.M. Bamer, K. Cetin, D. Amtmann, J.D. Bowen, and K.L. Johnson Comparing a self report questionnaire with physician assessment for determining multiple sclerosis clinical disease course: a validation study Multiple Sclerosis, September 1, 2007; 13(8): 1033 - 1037. [Abstract] [PDF]
|
|
|
|
|
|
K. Cetin, K.L. Johnson, D.M. Ehde, C.M. Kuehn, D. Amtmann, and G.H. Kraft Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample Multiple Sclerosis, September 1, 2007; 13(8): 1046 - 1053. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
